About nine months after the failure of its first coronavirus vaccine project, the Curevac company has now begun a clinical trial of its improved vaccine. The phase I study in the US will include up to 210 healthy adults, the German biotech company announced on Wednesday.
The first subject was vaccinated with the second-generation vaccine candidate – which Curevac is now developing in collaboration with British pharmaceutical company GlaxoSmithKline. The study will investigate the safety and magnitude of the immune response elicited by the vaccine at different doses.
Curevac expects results in the second half of this year. The company partnered with GlaxoSmithKline in the summer of 2020 to co-develop novel infectious disease vaccines based on CureVac’s second-generation mRNA technology.
First vaccine didn’t work as hoped
The biotech company was considered one of the big hopes of developing a Covid-19 vaccine, but suffered a serious setback when the vaccine didn’t work as well as hoped and the project was halted. In November, Curevac published the first promising preclinical data on its second-generation vaccine.
Source: Krone
I’m Wayne Wickman, a professional journalist and author for Today Times Live. My specialty is covering global news and current events, offering readers a unique perspective on the world’s most pressing issues. I’m passionate about storytelling and helping people stay informed on the goings-on of our planet.
